Feasibility and efficacy of local radiotherapy with concurrent novel agents in patients with multiple myeloma.

[1]  H. Asaoku,et al.  Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation , 2014, Acta Haematologica.

[2]  A. Jurczyszyn,et al.  Bortezomib for the treatment of multiple myeloma , 2014, Expert review of hematology.

[3]  M. Boccadoro,et al.  Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Tiedemann,et al.  Getting to the root of the problem: the causes of relapse in multiple myeloma , 2014, Expert review of anticancer therapy.

[5]  H. Einsele,et al.  The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients , 2014, Expert review of hematology.

[6]  Zihai Li,et al.  Fact or fiction - identifying the elusive multiple myeloma stem cell , 2013, Journal of Hematology & Oncology.

[7]  S. Demaria,et al.  An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer , 2013, Cancer Immunology Research.

[8]  G. Morgan,et al.  International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  B. Barlogie,et al.  Vertebral augmentation in the treatment of pathologic compression fractures in 792 patients with multiple myeloma , 2013, Leukemia.

[10]  S. Demaria,et al.  Radiation therapy to convert the tumor into an in situ vaccine. , 2012, International journal of radiation oncology, biology, physics.

[11]  N. Raje,et al.  Clinical trials of bisphosphonates in multiple myeloma. , 2012, Clinical advances in hematology & oncology : H&O.

[12]  C. Suh,et al.  Radiotherapy for solitary plasmacytoma of bone and soft tissue , 2012, Annals of Hematology.

[13]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[14]  D. Esseltine,et al.  Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  K. Anderson,et al.  The use of novel agents in the treatment of relapsed and refractory multiple myeloma , 2009, Leukemia.

[16]  D. Kallmes,et al.  Vertebroplasty in Multiple Myeloma: Outcomes in a Large Patient Series , 2008, American Journal of Neuroradiology.

[17]  Kenneth C Anderson,et al.  Lenalidomide and thalidomide: mechanisms of action--similarities and differences. , 2005, Seminars in hematology.

[18]  A. Dispenzieri,et al.  PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. , 2005, Experimental hematology.

[19]  T. Delaney,et al.  Severe Acute Enteritis in a Multiple Myeloma Patient Receiving Bortezomib and Spinal Radiotherapy: Case Report , 2005, Journal of chemotherapy.

[20]  D. Esseltine,et al.  A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma , 2004, British journal of haematology.

[21]  N. Munshi,et al.  NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.

[22]  S. Mose,et al.  Wertigkeit der Radiotherapie in der Behandlung des multiplen Myeloms , 2000, Strahlentherapie und Onkologie.

[23]  J. Kanis,et al.  Bisphosphonates in multiple myeloma , 2000, Cancer.

[24]  J. Yahalom,et al.  Radiotherapy in the management of plasma cell tumors. , 2000, Oncology.

[25]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[26]  J. Van Dyk,et al.  Radiosensitivity of human clonogenic myeloma cells and normal bone marrow precursors: effect of different dose rates and fractionation. , 1994, International journal of radiation oncology, biology, physics.

[27]  D. Shimm,et al.  Radiation therapy for the palliation of multiple myeloma. , 1993, International journal of radiation oncology, biology, physics.

[28]  I. Adamietz,et al.  Palliative radiotherapy in plasma cell myeloma. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[29]  D. Bertolini,et al.  Bone destruction and hypercalcemia in plasma cell myeloma. , 1986, Seminars in oncology.

[30]  P. Mclaughlin,et al.  Myeloma protein kinetics following chemotherapy. , 1982, Blood.

[31]  H. Wilson,et al.  Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. , 1969, JAMA.